SequelSEC

ZEVRA THERAPEUTICS, INC. ZVRA

Pharmaceutical Preparations · CIK 0001434647 · Fiscal year ends 1231

Revenue
$106.47M
Fiscal year ended 2025-12-31
Operating income
-$62.94M
Fiscal year ended 2025-12-31
Free cash flow
-$2.43M
Fiscal year ended 2025-12-31

ZEVRA THERAPEUTICS, INC. (ZVRA) reported revenue of $106.47M and net income of $83.23M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ZEVRA THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ZEVRA THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312015-12-312014-12-31
Revenue$106.47M$23.61M$27.46M$10.16M$28.65M$13.29M$12.84M$0$0$0
Cost of revenueUnavailableUnavailable$2.94M$222.00K$2.06MUnavailable$10.00M$0UnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable$9.94M$26.59MUnavailableUnavailable$0UnavailableUnavailable
Operating income-$62.94M-$87.00M-$49.60M-$42.56M$7.73M-$5.61M-$20.34M-$55.90M-$22.81M-$16.44M
Net income$83.23M-$105.51M-$46.05M-$26.77M-$8.56M-$12.76M-$24.52M-$56.47M-$54.66M-$24.46M
Research & developmentUnavailableUnavailableUnavailableUnavailable$10.16M$8.84M$19.42M$41.76M$13.93M$11.92M
Weighted-average diluted sharesshares 57.26Mshares 46.25MUnavailableUnavailableshares 29.77Mshares 3.98MUnavailableUnavailableUnavailableUnavailable
Pretax income$86.68M-$90.14M-$46.05M-$26.80M-$8.52M-$12.79M-$24.54M-$56.59M-$54.64M-$24.48M
Income tax expense$3.45M$15.37M$0-$33.00K$34.00K-$34.00K-$22.00K-$126.00K$26.00K-$22.00K
Diluted EPS$1.35$-2.28UnavailableUnavailable$-2.11$-3.21UnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$77.62M$54.87M$34.31M$15.04MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailable$15.34M$8.70M$7.92M$10.82M$12.51M$8.88M$4.53M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ZEVRA THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312015-12-312014-12-31
Cash & equivalents$62.41M$33.78M$43.05M$65.47M$112.35M$4.21M$3.22M$18.41M$32.32M$10.26M
Total assets$284.73M$178.13M$172.33M$115.34M$132.94M$11.21M$10.51M$26.75M$54.59M$13.71M
Current assets$223.01M$86.03M$86.94M$92.83M$115.06M$8.38M$6.97M$23.72M$54.08M$10.28M
Total liabilities$130.07M$138.46M$110.46M$40.22M$5.82M$77.62M$84.96M$93.31M$64.71M$38.02M
Current liabilities$39.28M$34.06M$73.72M$12.02M$4.23M$7.54M$5.43M$12.00M$8.34M$3.94M
Total equity incl. NCI$154.66M$39.67M$61.86M$75.12M$101.66M-$66.41M-$74.46M-$66.57M-$10.12M-$48.51M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$24.21M
Inventory$1.74M$1.97M$0$671.00KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$10.18M$16.12M$7.18M$1.42M$2.44M$1.68M$0UnavailableUnavailable
Goodwill$4.70M$4.70M$4.70M$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$61.93M$59.50M$5.07MUnavailableUnavailable$67.66M$77.34M$81.44MUnavailableUnavailable
Accounts payable$2.48M$13.08M$13.99M$3.61M$516.00K$1.17M$1.14M$3.72M$1.25M$1.58M

Cash flow

ZEVRA THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312015-12-312014-12-31
Operating cash flow-$1.60M-$69.66M-$33.54M-$18.72M$10.44M-$1.94M-$23.74M-$54.20M-$20.27MUnavailable
Capital expenditures$835.00K$0$296.00K$93.00K$102.00K$33.00K$26.00K$21.00K$135.00K$47.00K
Investing cash flow$18.13M-$22.16M-$17.39M-$36.72M-$15.52M-$33.00K$3.23M$33.33M-$19.14MUnavailable
Financing cash flow$12.06M$82.11M$28.46M$8.35M$113.11M$2.74M$4.94M$28.02M$61.47MUnavailable
Net change in cash$28.62M-$9.26M-$22.42M-$46.88M$108.02M$767.00K-$15.56M$7.15M$22.06M$8.29M
Stock-based compensation$12.63M$14.91M$5.95M$4.29M$2.44M$2.49M$4.41M$6.50M$2.37M$214.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailable$0$3.45M$4.72M$2.81M$0UnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$4.05M$6.39M$1.01M$944.00K$257.00K$273.00K$304.00K$324.00K$84.00K$75.00K

Derived

ZEVRA THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312015-12-312014-12-31
Free cash flow-$2.43M-$69.66M-$33.83M-$18.81M$10.34M-$1.97M-$23.76M-$54.22M-$20.40MUnavailable
Gross marginUnavailableUnavailableUnavailable97.8%92.8%UnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-59.1%-368.5%-180.6%-418.9%27.0%-42.2%-158.4%UnavailableUnavailableUnavailable
FCF margin-2.3%-295.0%-123.2%-185.1%36.1%-14.8%-185.1%UnavailableUnavailableUnavailable
SBC / revenue11.9%63.1%21.7%42.3%8.5%18.7%34.3%UnavailableUnavailableUnavailable
Current ratio5.68x2.53x1.18x7.72x27.20x1.11x1.28x1.98x6.48x2.61x
Revenue YoY growth350.9%-14.0%170.3%-64.5%115.6%3.5%UnavailableUnavailableUnavailableUnavailable
Net margin78.2%-446.9%-167.7%-263.5%-29.9%-96.0%-191.0%UnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable66.5%151.2%UnavailableUnavailableUnavailable
CapEx / revenue0.8%0.0%1.1%0.9%0.4%0.2%0.2%UnavailableUnavailableUnavailable
Long-term debt / equity0.40xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate4.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZVRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2019-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

balance equationreview2021-12-31

Difference 25458000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.